Premier Graphene Inc BIEI

CEO Update Letter – October, 2018

[badgirl007]

Posted at October 31, 2018 | By : Admin | Categories : Blog,Investor News,Investor Relations,Press Releases | 0 Comment 

Greetings From The CEO And Staff At Premier Biomedical! 
This quarter’s CEO Letter reflects a summary of two recent interviews; one on MoneyTV and the other on Uptick Newswire’s Stock Day” program. 

Finance and Stock Performance 
• We have been negotiating Non-Dilutive Financing, but can’t say more at this time. We have verified that our bank will make loans available to us at very low rates based on purchase orders in-hand. 

• Non-Dilutive Investment. We have created Six Centers of Technology Expertise (Investment Opportunities) in which we will offer investors a percentage of licensing and/or commercialization revenue, not an equity position. 

• Our recent actions have attracted the attention and interest of some large companies. We will have more to say on this in the future. 

Pain Management. 
• This past quarter, we continued to promote sales of our industry-leading topical pain relief products through our website at www.painreliefmeds.com. 

• Our team of sales professionals of former pharmacy sales personnel and Purchasing agents from the Department of Defense and the government continue their efforts to interest government agencies and long term health care facilities in the use of our all-natural, 50-state legal, hemp oil/CBD topical pain relief products as an alternative to dangerous and addictive pain pills. 

• An anticipated boost to CBD topical products is expected upon passage of the pending Senate Bill #S-2667, which clarifies hemp derived CBD as federally legal and acceptable for use in certain medical applications. The bill is out of committee and is expected to come to the floor for a vote after the mid-terms. 

• We are still in negotiations to form a potential Joint Venture in Europe as an outlet for our topical pain relief products. 

• I recently met with representatives from three large potential distributors for our products. One specializes in pharmacies and medical facilities; the second specializes in convenience stores and travel centers, and the third specializes in medium and large stores. We believe that adding direct sales outlets to our existing on-line sales channel will significantly increase sales and revenue. 

• We have been developing introductory, smaller size versions of our roll-on and ointment, along with additional innovative new introductory products which we expect to introduce in the coming months. This will expand our current line of topical pain relief products into additional segments of the market. 

Investor/Public Relations Programs. 
• We have retained our relationship with G.S. Whitney, Uptick Newswire and Money TV to promote our investor relations. 

• We have retained Green Group Studio of Florida to coordinate and enhance our social media presence 

SUMMARY 
In summary, we see a bright future for Premier Biomedical because: 

1. We have two issued patents on the use of anti-bodies to combat disease without dangerous side-effects. 

2. We have an issued patent on a drug we named Feldetrex (In honor of the inventor and our co-founder, Dr. Mitchell Felder) which has multiple usage potentials in drug and chemical addiction, and other applications, particularly when used in combination with cannabinoid products. 

3. We are seeking a European alliance that will open up that market to our hemp oil/CBD topical pain products. 

4. The world is actively seeking an all-natural alternative to dangerous and addictive opioid pain products. 

5. Governmental actions to date to drastically reduce the availability of prescription opioid pain pills are only speeding up the process of pain sufferers to revert to Heroin. 

6. Premier Biomedical topical pain products are all-natural, 50-state-legal, pesticide- and solvent-free, and have more pain-relieving CBD content than principal competitors. 

7. Our revised product and pricing strategies to focus on large distributors encompassing retail outlets including pharmacies, small convenience stores and large and medium outlets will dramatically increase our product sales and revenue. 

8. Better coordination of social media will insure that our message is getting out to the public through all current outlets. 

9. We continue our relationship with the best IR/PR firms that we have experienced to date. 

There are a lot of potentially huge developments in process currently which could significantly improve Premier Biomedical’s status, and we will keep you apprised of them as they come to fruition. 

Thank you for your patience and support. 

Sincerely, 

William A. Hartman 
President and CEO 
Premier Biomedical Inc. 
[phone] 
[e-mail] 
https://www.premierbiomedical.com/